ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
34 announcements with these filters
Neuland commissioned its first commercial peptide manufacturing module with 7,000L reactor capacity. Module two expansion is underway to meet rising customer demand for peptide APIs.
Neuland Laboratories' board approved ₹126 Crore capex to acquire 134 acres of land in Andhra Pradesh for future expansion. The company holds ROFR on additional land.
Neuland Laboratories announced that CRISIL Ratings has reaffirmed its long-term credit rating at CRISIL A+/Positive and its short-term rating at CRISIL A1.
Malabar India Fund Limited sold 2,72,634 equity shares of Neuland Laboratories Ltd via open market. This transaction reduces their stake from 7.18% to 5.06%.
Neuland Laboratories announced the completion of a US FDA inspection at its Unit 3 facility. The regulator issued a Form 483 with one procedural observation.
Q1FY27 was broadly in line with expectations, showing strong YoY revenue and profit growth. Management remains confident in achieving a 20% growth rate despite inherent quarterly volatility in the CMS business.
Neuland Laboratories will provide a Rs. 40 Crore corporate guarantee to Gland Pharma Limited to secure obligations under a new Loan Licence Agreement for manufacturing capacity.
Neuland Laboratories will provide a corporate guarantee of Rs. 40 crore to Gland Pharma Limited. This supports obligations under a new Loan Licence Agreement.
Neuland Laboratories Ltd announced a capacity expansion of 18 KL at an investment of ₹39.80 Crore. This expansion aims to meet growing customer demand.
Neuland reported Q1FY27 total income of ₹650.1 Cr (116.3% YoY growth) with an EBITDA margin of 35.5%. Growth is driven by the CMS business and commercial molecules.
Neuland Laboratories reported Q1 FY27 total income of ₹650.1 crore and EBITDA of ₹231.1 crore. The company highlights strong performance across CMS and GDS businesses.
Neuland Laboratories Ltd reported revenue from operations of ₹641.6 Cr (+119.1% YoY) and net profit of ₹147.7 Cr (+962.6% YoY) for Q1 FY27.
Neuland Laboratories held its 42nd Annual General Meeting on August 4, 2026. Shareholders approved all resolutions, including the final dividend declaration.
Neuland Laboratories has commenced commercial production for its additional capacities at Unit 1 and Unit 3 in Telangana, marking the completion of its expansion plans.
Neuland Laboratories has scheduled a Board Meeting for August 5, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Neuland Laboratories reported the loss of a share certificate for shareholder Ram Chander Gupta. The company is processing the issuance of an entitlement letter.
Neuland Laboratories Ltd has filed its quarterly shareholding pattern report as required under SEBI regulations for the period ended June 30, 2026.
India Ratings and Research affirmed Neuland Laboratories' bank loan ratings at IND A+ with a positive outlook. This affirmation reflects stable creditworthiness for the company.
Neuland Laboratories issued a web-link notice for its 42nd AGM and FY 2025-26 Integrated Annual Report. This facilitates access for shareholders with unregistered email addresses.
Neuland Laboratories submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG performance and operational metrics.
Neuland Laboratories released its FY 2025-26 Integrated Annual Report. The company reported an API manufacturing capacity of 1,226 KL across three US FDA compliant facilities.
Neuland Laboratories convened its 42nd AGM for August 4, 2026. Agenda includes adopting financial statements and declaring a ₹34 per share final dividend.
Neuland reported record performance for Q4FY26, driven by high-value CMS commercial projects and favorable exchange rates, achieving an exceptional 40.5% EBITDA margin.
Neuland Laboratories' March 2026 API Product List showcases a robust portfolio across diverse therapeutic segments including anticoagulants, antipsychotics, and peptides.
Neuland Laboratories issued a correction fixing a typographical error in its FY26 press release header. Financial data remains unchanged from the original results disclosure.
Neuland Laboratories appointed Dr. Mauricio Futran as a Non-Executive Director effective May 12, 2026. He brings over 40 years of pharmaceutical manufacturing and strategic development experience.
Neuland Laboratories recommended a final dividend of ₹34 per equity share for 2026. The record date is July 24, with payment expected by August 19.
Neuland Laboratories delivered strong FY26 results with significant revenue and profit scaling, driven by the CMS business and commercial molecules. Strategy focuses on high-margin niches, peptides, and a new R&D center.
Neuland Laboratories reported FY26 total income of ₹2053.1 Crore and EBITDA of ₹603.4 Crore. Annual performance shows strong execution discipline and positive business visibility.
Neuland Laboratories Ltd reported revenue from operations of ₹776.3 Cr (+136.4% YoY) and net profit of ₹212.7 Cr (+665.1% YoY) for Q4 FY26.